These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 17430224)

  • 1. Fondaparinux: pharmacology and clinical experience in cardiovascular medicine.
    Toschi V; Lettino M
    Mini Rev Med Chem; 2007 Apr; 7(4):383-7. PubMed ID: 17430224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the pharmacological properties and clinical results of the synthetic pentasaccharide (fondaparinux).
    Samama MM; Gerotziafas GT
    Thromb Res; 2003 Jan; 109(1):1-11. PubMed ID: 12679126
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fondaparinux: use in thromboprophylaxis of acute medical patients.
    Dhillon S; Plosker GL
    Drugs Aging; 2008; 25(1):81-8. PubMed ID: 18184032
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fondaparinux.
    Tan KT; Lip GY
    Curr Pharm Des; 2005; 11(4):415-9. PubMed ID: 15725062
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fondaparinux: an overview.
    Nadar SK; Goyal D; Shantsila E; Banerjee P; Lip GY
    Expert Rev Cardiovasc Ther; 2009 Jun; 7(6):577-85. PubMed ID: 19505272
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factor X inhibitors.
    Tan KT; Makin A; Lip GY
    Expert Opin Investig Drugs; 2003 May; 12(5):799-804. PubMed ID: 12720491
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fondaparinux sodium: a review of its use in the treatment of acute venous thromboembolism.
    Robinson DM; Wellington K
    Am J Cardiovasc Drugs; 2005; 5(5):335-46. PubMed ID: 16156690
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The safety of fondaparinux for the prevention and treatment of venous thromboembolism.
    Turpie AG
    Expert Opin Drug Saf; 2005 Jul; 4(4):707-21. PubMed ID: 16011449
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fondaparinux: basic properties and efficacy and safety in venous thromboembolism prophylaxis.
    Bauer KA
    Am J Orthop (Belle Mead NJ); 2002 Nov; 31(11 Suppl):4-10. PubMed ID: 12463577
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the effect of fondaparinux and enoxaparin on thrombin generation during in-vitro clotting of whole blood and platelet-rich plasma.
    Gerotziafas GT; Depasse F; Chakroun T; Van Dreden P; Samama MM; Elalamy I
    Blood Coagul Fibrinolysis; 2004 Mar; 15(2):149-56. PubMed ID: 15091002
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The synthetic pentasaccharide fondaparinux: first in the class of antithrombotic agents that selectively inhibit coagulation factor Xa.
    Petitou M; Duchaussoy P; Herbert JM; Duc G; El Hajji M; Branellec JF; Donat F; Necciari J; Cariou R; Bouthier J; Garrigou E
    Semin Thromb Hemost; 2002 Aug; 28(4):393-402. PubMed ID: 12244487
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fondaparinux sodium: a selective inhibitor of factor Xa.
    Bauer KA
    Am J Health Syst Pharm; 2001 Nov; 58 Suppl 2():S14-7. PubMed ID: 11715834
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functionality of fondaparinux (pentasaccharide) depends on clinical antithrombin levels.
    Jeske WP; Walenga JM; Samama MM; Hoppensteadt D; Mayuga M; Fareed J
    Blood Coagul Fibrinolysis; 2011 Apr; 22(3):206-10. PubMed ID: 21297455
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Preclinical and clinical data of the synthetic Xa inhibitor fondaparinux (Arixtra(®))].
    Suzuki I; Ozeki Y
    Nihon Yakurigaku Zasshi; 2012 Mar; 139(3):117-26. PubMed ID: 22451467
    [No Abstract]   [Full Text] [Related]  

  • 15. Fondaparinux for prevention of venous thromboembolism in major orthopedic surgery.
    Tran AH; Lee G
    Ann Pharmacother; 2003 Nov; 37(11):1632-43. PubMed ID: 14565815
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Fondaparinux: the present and the future].
    Garcia Hejl C; Garcia C; Thefenne-Astier H; Servonnet A; Samson T; Foissaud V
    Pathol Biol (Paris); 2008 Mar; 56(2):97-103. PubMed ID: 18178332
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Setting a standard for venous thromboembolism prophylaxis.
    Turpie AG
    Am J Health Syst Pharm; 2001 Nov; 58 Suppl 2():S18-23. PubMed ID: 11715835
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fondaparinux: a Factor Xa inhibitor for antithrombotic therapy.
    Turpie AG
    Expert Opin Pharmacother; 2004 Jun; 5(6):1373-84. PubMed ID: 15163281
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SAfety of Fondaparinux in transoesophageal echocardiography-guided Electric cardioversion of Atrial Fibrillation (SAFE-AF) study: a pilot study.
    Cohen A; Stellbrink C; Le Heuzey JY; Faber T; Aliot E; Banik N; Kropff S; Omran H;
    Arch Cardiovasc Dis; 2015 Feb; 108(2):122-31. PubMed ID: 25684570
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PK evaluation of fondaparinux sodium for the treatment of thrombosis.
    Delavenne X; Frappé P; Zufferey P; Mismetti P; Laporte S; Bertoletti L
    Expert Opin Drug Metab Toxicol; 2014 Feb; 10(2):269-77. PubMed ID: 24359588
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.